Progress in pharmacogenomics and efficacy prediction of levetiracetam / 中华神经科杂志
Chinese Journal of Neurology
;
(12): 973-978, 2021.
Artículo
en Chino
| WPRIM
| ID: wpr-911824
ABSTRACT
Levetiracetam (LEV) is the second generation of broad-spectrum antiepileptic drugs. Compared with other antiepileptic drugs, LEV has unique antiepileptic mechanism, good efficacy and tolerance, and its target is synaptic vesicle protein 2A. With the widespread use of LEV, more and more adverse reactions have been reported, especially mental related adverse reactions. This paper reviewed the research progress of LEV pharmacogenomics related targets, metabolism, adverse reaction related genetic variation and efficacy prediction, so as to provide decision-making for the application of LEV individualized treatment in clinical practice, improve the quality of life of epileptic patients and reduce the disease burden of patients with epilepsy.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Estudio pronóstico
Idioma:
Chino
Revista:
Chinese Journal of Neurology
Año:
2021
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS